Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer.

Glaser SM, Kalash R, Bongiorni DR, Roberts MS, Balasubramani GK, Jacobs BL, Beriwal S, Heron DE, Greenberger JS.

In Vivo. 2018 Jan-Feb;32(1):113-120.

PMID:
29275307
2.

Evidence-Based Reporting: A Method to Optimize Prostate MRI Communications With Referring Physicians.

Magnetta MJ, Donovan AL, Jacobs BL, Davies BJ, Furlan A.

AJR Am J Roentgenol. 2018 Jan;210(1):108-112. doi: 10.2214/AJR.17.18260. Epub 2017 Nov 1.

PMID:
29091009
3.

Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3.

Koehler H, Cotsmire S, Langland J, Kibler KV, Kalman D, Upton JW, Mocarski ES, Jacobs BL.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11506-11511. doi: 10.1073/pnas.1700999114. Epub 2017 Oct 9.

PMID:
29073079
4.

Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care.

Borza T, Kaufman SR, Yan P, Herrel LA, Luckenbaugh AN, Miller DC, Skolarus TA, Jacobs BL, Hollingsworth JM, Norton EC, Shahinian VB, Hollenbeck BK.

Cancer. 2018 Feb 1;124(3):563-570. doi: 10.1002/cncr.31081. Epub 2017 Oct 20.

PMID:
29053177
5.

The Comparative Effectiveness of Treatments for Ureteropelvic Junction Obstruction.

Jacobs BL, Lai JC, Seelam R, Hanley JM, Wolf JS Jr, Hollenbeck BK, Hollingsworth JM, Dick AW, Setodji CM, Saigal CS; Urologic Diseases in America Project.

Urology. 2018 Jan;111:72-77. doi: 10.1016/j.urology.2017.09.002. Epub 2017 Sep 21.

PMID:
28943371
6.

Characterization of a PKR inhibitor from the pathogenic ranavirus, Ambystoma tigrinum virus, using a heterologous vaccinia virus system.

Huynh TP, Jancovich JK, Tripuraneni L, Heck MC, Langland JO, Jacobs BL.

Virology. 2017 Nov;511:290-299. doi: 10.1016/j.virol.2017.08.012. Epub 2017 Sep 14.

PMID:
28919326
7.

Preoperative immunonutrition prior to radical cystectomy: a pilot study.

Lyon TD, Turner I I RM, McBride D, Wang L, Gingrich JR, Hrebinko RL, Jacobs BL, Davies BJ, Tarin TV.

Can J Urol. 2017 Aug;24(4):8895-8901.

PMID:
28832307
8.

Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.

Hollenbeck BK, Kaufman SR, Yan P, Herrel LA, Borza T, Schroeck FR, Jacobs BL, Skolarus TA, Shahinian VB.

Eur Urol. 2017 Aug 18. pii: S0302-2838(17)30687-5. doi: 10.1016/j.eururo.2017.08.001. [Epub ahead of print]

PMID:
28823605
9.

Editorial Comment: Industry Payments to Urologists in 2014: an Analysis of the Open Payments Program.

Bandari J, Jacobs BL.

Urol Pract. 2017 Jul;4(4):347. No abstract available.

10.

The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-readmission Interval.

Krishnan N, Li B, Jacobs BL, Ambani SN, Borza T, He C, Hollenbeck BK, Morgan T, Hafez KS, Weizer AZ, Montgomery JS, Lee CT, Lesse O, Lavieri MS, Helm JE, Skolarus TA.

Eur Urol Focus. 2016 Aug 4. pii: S2405-4569(16)30102-X. doi: 10.1016/j.euf.2016.07.004. [Epub ahead of print]

PMID:
28753778
11.

The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.

Bandari J, Ayyash OM, Turner RM 2nd, Jacobs BL, Davies BJ.

Cancer. 2017 Nov 15;123(22):4356-4362. doi: 10.1002/cncr.30914. Epub 2017 Jul 27.

PMID:
28749536
12.

Variation in readmission expenditures after high-risk surgery.

Jacobs BL, He C, Li BY, Helfand A, Krishnan N, Borza T, Ghaferi AA, Hollenbeck BK, Helm JE, Lavieri MS, Skolarus TA.

J Surg Res. 2017 Jun 1;213:60-68. doi: 10.1016/j.jss.2017.02.017. Epub 2017 Feb 23.

PMID:
28601334
13.

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.

Meador LR, Kessans SA, Kilbourne J, Kibler KV, Pantaleo G, Roderiguez ME, Blattman JN, Jacobs BL, Mor TS.

Virology. 2017 Jul;507:242-256. doi: 10.1016/j.virol.2017.04.008. Epub 2017 Apr 28.

14.

Comparative effectiveness in urology: a state of the art review utilizing a systematic approach.

Bandari J, Wessel CB, Jacobs BL.

Curr Opin Urol. 2017 Jul;27(4):380-394. doi: 10.1097/MOU.0000000000000405.

PMID:
28426464
15.

Epidemiology of the Small Renal Mass and the Treatment Disconnect Phenomenon.

Turner RM 2nd, Morgan TM, Jacobs BL.

Urol Clin North Am. 2017 May;44(2):147-154. doi: 10.1016/j.ucl.2016.12.001. Epub 2017 Mar 14. Review.

PMID:
28411907
16.

Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.

Schroeck FR, Jacobs BL, Bhayani SB, Nguyen PL, Penson D, Hu J.

Eur Urol. 2017 Nov;72(5):712-735. doi: 10.1016/j.eururo.2017.03.028. Epub 2017 Mar 31. Review.

PMID:
28366513
17.

The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.

Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Schroeck FR, Bekelman JE, Kahn JM, Nelson JB, Barnato AE.

Cancer. 2017 Aug 1;123(15):2945-2954. doi: 10.1002/cncr.30574. Epub 2017 Mar 16.

PMID:
28301689
18.

Identification of mechanically regulated phosphorylation sites on tuberin (TSC2) that control mechanistic target of rapamycin (mTOR) signaling.

Jacobs BL, McNally RM, Kim KJ, Blanco R, Privett RE, You JS, Hornberger TA.

J Biol Chem. 2017 Apr 28;292(17):6987-6997. doi: 10.1074/jbc.M117.777805. Epub 2017 Mar 13.

PMID:
28289099
19.

No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care.

Borza T, Jacobs BL, Montgomery JS, Weizer AZ, Morgan TM, Hafez KS, Lee CT, Li BY, Min HS, He C, Gilbert SM, Helm JE, Lavieri MS, Hollenbeck BK, Skolarus TA.

Urology. 2017 Jun;104:77-83. doi: 10.1016/j.urology.2017.01.042. Epub 2017 Mar 4.

PMID:
28267606
20.

Variations in Preoperative Use of Bone Scan Among Medicare Beneficiaries Undergoing Radical Cystectomy.

Turner RM 2nd, Yabes JG, Davies BJ, Heron DE, Jacobs BL.

Urology. 2017 May;103:84-90. doi: 10.1016/j.urology.2017.02.028. Epub 2017 Feb 24.

PMID:
28238757
21.

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M.

J Virol. 2017 Apr 13;91(9). pii: e02182-16. doi: 10.1128/JVI.02182-16. Print 2017 May 1.

22.

The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab.

Bandari J, Turner RM 2nd, Jacobs BL, Canes D, Moinzadeh A, Davies BJ.

Urol Pract. 2017 Jan;4(1):14-20. doi: 10.1016/j.urpr.2016.03.007.

23.

Prognostic implications of immediate PSA response to early salvage radiotherapy.

Turner I I RM, Yabes JG, Woldemichael E, Deutsch MM, Smith RP, Werner RS, Jacobs BL, Nelson JB.

Can J Urol. 2016 Dec;23(6):8568-8575.

PMID:
27995853
24.

Variation in the Use of Open Pyeloplasty, Minimally Invasive Pyeloplasty, and Endopyelotomy for the Treatment of Ureteropelvic Junction Obstruction in Adults.

Jacobs BL, Lai JC, Seelam R, Hanley JM, Wolf JS Jr, Hollenbeck BK, Hollingsworth JM, Dick AW, Setodji CM, Saigal CS.

J Endourol. 2017 Feb;31(2):210-215. doi: 10.1089/end.2016.0688. Epub 2017 Jan 5.

25.

Cost Analysis of Treatments for Ureteropelvic Junction Obstruction.

Jacobs BL, Seelam R, Lai JC, Hanley JM, Wolf JS Jr, Hollenbeck BK, Hollingsworth JM, Dick AW, Setodji CM, Saigal CS.

J Endourol. 2017 Feb;31(2):204-209. doi: 10.1089/end.2016.0722. Epub 2017 Jan 5.

26.

Biopsy Perineural Invasion in Prostate Cancer Patients Who Are Candidates for Active Surveillance by Strict and Expanded Criteria.

Turner RM 2nd, Yecies TS, Yabes JG, Ristau BT, Woldemichael E, Davies BJ, Jacobs BL, Nelson JB.

Urology. 2017 Apr;102:173-177. doi: 10.1016/j.urology.2016.11.011. Epub 2016 Nov 15.

PMID:
27864108
27.

Predictors of Delayed Intervention for Patients on Active Surveillance for Small Renal Masses: Does Renal Mass Biopsy Influence Our Decision?

Ambani SN, Morgan TM, Montgomery JS, Gadzinski AJ, Jacobs BL, Hawken S, Krishnan N, Caoili EM, Ellis JH, Kunju LP, Hafez KS, Miller DC, Palapattu GS, Weizer AZ, Wolf JS Jr.

Urology. 2016 Dec;98:88-96. doi: 10.1016/j.urology.2016.04.067. Epub 2016 Jul 19.

PMID:
27450936
28.

Urology Payments from Industry in the Sunshine Act.

Bandari J, Turner RM 2nd, Jacobs BL, Davies BJ.

Urol Pract. 2016 Sep;3(5):332-337.

29.

Molecular Cytogenetics as a Diagnostic Aid for Primary Liposarcoma of the Spermatic Cord.

Hugar LA, Quiroga-Garza GM, Davies BJ, Hrebinko RL, Tran T, Jacobs BL.

Clin Genitourin Cancer. 2017 Feb;15(1):e83-e89. doi: 10.1016/j.clgc.2016.08.008. Epub 2016 Aug 10. No abstract available.

PMID:
27666164
30.

Payments to Pediatricians in the Sunshine Act.

Karas DJ, Bandari J, Browning DN, Jacobs BL, Davies BJ.

Clin Pediatr (Phila). 2017 Jul;56(8):723-728. doi: 10.1177/0009922816670981. Epub 2016 Sep 23.

PMID:
27663966
31.

Preoperative Statin Use at the Time of Radical Prostatectomy Is Not Associated With Biochemical Recurrence or Pathologic Upgrading.

Lyon TD, Turner RM 2nd, Yabes JG, Woldemichael E, Davies BJ, Jacobs BL, Nelson JB.

Urology. 2016 Nov;97:153-159. doi: 10.1016/j.urology.2016.08.004. Epub 2016 Aug 8.

PMID:
27516122
32.

Local coverage determination policy and the use of stereotactic body radiation therapy for prostate cancer.

Jacobs BL, Sunderland R, Yabes J, Nelson JB, Barnato AE, Bekelman JE.

Urol Pract. 2015 Nov;2(6):304-311.

33.

Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus.

Arndt WD, White SD, Johnson BP, Huynh T, Liao J, Harrington H, Cotsmire S, Kibler KV, Langland J, Jacobs BL.

Virology. 2016 Oct;497:125-135. doi: 10.1016/j.virol.2016.07.016. Epub 2016 Jul 26.

34.

Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population.

Jacobs BL, Lopa SH, Yabes JG, Nelson JB, Barnato AE, Degenholtz HB.

Cancer. 2016 Oct 15;122(20):3199-3206. doi: 10.1002/cncr.30184. Epub 2016 Jul 5.

35.

Panniculectomy and Cystectomy: An Approach to the Morbidly Obese Patient.

Hugar LA, Turner RM, Gusenoff JA, Correa AF, Jacobs BL, Davies BJ.

Case Rep Urol. 2016;2016:6980843. doi: 10.1155/2016/6980843. Epub 2016 Apr 18.

36.

Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.

Zurawski G, Zurawski S, Flamar AL, Richert L, Wagner R, Tomaras GD, Montefiori DC, Roederer M, Ferrari G, Lacabaratz C, Bonnabau H, Klucar P, Wang Z, Foulds KE, Kao SF, Yates NL, LaBranche C, Jacobs BL, Kibler K, Asbach B, Kliche A, Salazar A, Reed S, Self S, Gottardo R, Galmin L, Weiss D, Cristillo A, Thiebaut R, Pantaleo G, Levy Y.

PLoS One. 2016 Apr 14;11(4):e0153484. doi: 10.1371/journal.pone.0153484. eCollection 2016.

37.

Partial and hemi-nephrectomy for renal malignancy in patients with horseshoe kidney.

Yecies T, Turner Іi RM, Ferroni MC, Jacobs BL, Davies BJ.

Can J Urol. 2016 Feb;23(1):8156-9.

PMID:
26892057
38.

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.

Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R.

J Virol. 2016 Mar 28;90(8):4133-49. doi: 10.1128/JVI.03135-15. Print 2016 Apr.

39.

A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy.

Krishnan N, Liu X, Lavieri MS, Hu M, Helfand A, Li B, Helm JE, He C, Hollenbeck BK, Skolarus TA, Jacobs BL.

J Urol. 2016 May;195(5):1362-7. doi: 10.1016/j.juro.2015.11.063. Epub 2015 Dec 10.

PMID:
26682758
40.

Short-term Outcomes of Intraoperative Cell Saver Transfusion During Open Partial Nephrectomy.

Lyon TD, Ferroni MC, Turner RM 2nd, Jones C, Jacobs BL, Davies BJ.

Urology. 2015 Dec;86(6):1153-8. doi: 10.1016/j.urology.2015.09.008. Epub 2015 Sep 24.

PMID:
26387849
41.

Evasion of the Innate Immune Type I Interferon System by Monkeypox Virus.

Arndt WD, Cotsmire S, Trainor K, Harrington H, Hauns K, Kibler KV, Huynh TP, Jacobs BL.

J Virol. 2015 Oct;89(20):10489-99. doi: 10.1128/JVI.00304-15. Epub 2015 Aug 5.

42.

A Generalized Assessment of the Impact of Regionalization and Provider Learning on Patient Outcomes.

Zhang Y, Lee SY, Gilleskie DB, Sun Y, Padakandla A, Jacobs BL, Montgomery JS, Montie JE, Wei JT, Hollenbeck BK.

Med Decis Making. 2016 Nov;36(8):990-8. doi: 10.1177/0272989X15593282. Epub 2015 Jul 13.

PMID:
26169752
43.

Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity.

McAfee MS, Huynh TP, Johnson JL, Jacobs BL, Blattman JN.

Virology. 2015 Oct;484:153-62. doi: 10.1016/j.virol.2015.05.021. Epub 2015 Jun 20.

44.

Yes-Associated Protein is up-regulated by mechanical overload and is sufficient to induce skeletal muscle hypertrophy.

Goodman CA, Dietz JM, Jacobs BL, McNally RM, You JS, Hornberger TA.

FEBS Lett. 2015 Jun 4;589(13):1491-7. doi: 10.1016/j.febslet.2015.04.047. Epub 2015 May 8.

45.

Radical versus partial nephrectomy.

Jacobs BL, Davies BJ.

Health Aff (Millwood). 2015 May;34(5):881. doi: 10.1377/hlthaff.2015.0276. No abstract available.

PMID:
25941293
46.

The prone ureteroscopic technique for managing large stone burdens.

Sternberg KM, Jacobs BL, King BJ, Wachterman JB, Shahrour K, Theisen KM, Sprauer SE, Ohmann E, Averch TD.

Can J Urol. 2015 Apr;22(2):7758-62.

47.

Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1.

Mooij P, Koopman G, Drijfhout JW, Nieuwenhuis IG, Beenhakker N, Koestler J, Bogers WM, Wagner R, Esteban M, Pantaleo G, Heeney JL, Jacobs BL, Melief CJ.

J Gen Virol. 2015 Jun;96(Pt 6):1478-83. doi: 10.1099/vir.0.000074. Epub 2015 Feb 9.

PMID:
25667320
48.

Understanding hospital readmission intensity after radical cystectomy.

Skolarus TA, Jacobs BL, Schroeck FR, He C, Helfand AM, Helm J, Hu M, Lavieri M, Hollenbeck BK.

J Urol. 2015 May;193(5):1500-6. doi: 10.1016/j.juro.2014.10.107. Epub 2014 Nov 4.

PMID:
25451833
49.

Technology diffusion and prostate cancer quality of care.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Zhang Y, Hollenbeck BK.

Urology. 2014 Nov;84(5):1066-72. doi: 10.1016/j.urology.2014.06.067. Epub 2014 Oct 24.

50.

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J, Mejías-Pérez E, Jiménez V, Sánchez C, Sorzano CÓ, Oliveros JC, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler KV, Jacobs BL, Pantaleo G, Esteban M.

J Virol. 2015 Jan 15;89(2):970-88. doi: 10.1128/JVI.02469-14. Epub 2014 Oct 29.

Supplemental Content

Loading ...
Support Center